Short interest for Icon gives investors a sense of the degree to which investors are betting on the decline of Icon's stock. Short interest data is updated every two weeks.

Icon Stock (NASDAQ:ICLR), Short Interest Report

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACVA

ALTI

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

DELL

DOCN

ICLR

INDV

LNTH

MATV

MRNA

NICE

NVAX

NVDA

OCUL

QTWO

RELY

RILY

ROOT

SMCI

SNPS

WING

U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.

NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday

Price Target

Pre-Market Outlook

Analyst Ratings

CYBR

DLTR

SCHW

SPWR

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Lennox International To Rally 22%? Here Are 10 Top Analyst Forecasts For Tuesday

Long Ideas

Media

PYPL

UBER

On CNBC’s &#34;Halftime Report Final Trades,&#34;  Stephen Weiss  of Short Hills Capital Partners said  Uber Technologies, Inc.

Uber Technologies, Blackstone And A Major Healthcare Company: CNBC&#39;s &#39;Final Trades&#39;

Icon PLC

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=53968413&amp;newsitemid=20240430675153&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=0c82fd737039557352788a913a0e252e">ICON plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) ("ICON"), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the "Notes").
The Notes will be issued by ICON's wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the "Issuer"), and will be guaranteed on a senior secured basis by ICON and its existing and future wholly owned subsidiaries organized in the United States, Ireland and the Grand Duchy of Luxembourg ("Luxembourg") (the "Subsidiary Guarantors" and, collectively with ICON, the "Guarantors"), in each case that guarantee the obligations under our senior secured U.S. dollar denominated term loan facility and senior secured revolving credit facility (together, the "Senior Secured Credit Facilities") and the 2.875% senior secured notes due 2026 issued by PRA Health Sciences, Inc., a wholly owned subsidiary of ICON (the "Existing Notes"). The Notes will be senior secured obligations of the Issuer and the Guarantors and the Notes will rank equally in right of payment to all of the Issuer's and Guarantors' existing and future senior debt (including the Senior Secured Credit Facilities and the Existing Notes) and senior in right of payment to all of the Issuer's and Guarantors' existing and future subordinated debt.
The offering is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.

Offerings

ICON Announces Pricing Of $2B Notes

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 5 years by 4.98% on an annualized basis producing an average annual return of 16.62%. Currently, Icon has a market capitalization of $25.57 billion. 
Buying $1000 In ICLR: If an investor had bought $1000 of ICLR stock 5 years ago, it would be worth $2,172.41 today based on a price of $309.22 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714404628_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

TD Cowen analyst Charles Rhyee maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and raises the price target from $343 to $349.

TD Cowen Maintains Buy on Icon, Raises Price Target to $349

Evercore ISI Group analyst Ross Muken maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $350 to $330.

Evercore ISI Group Maintains Outperform on Icon, Lowers Price Target to $330

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and raises the price target from $362 to $363.

Baird Maintains Outperform on Icon, Raises Price Target to $363

Earnings

Icon Q1 2024 GAAP EPS $2.25 Beats $2.10 Estimate, Sales $2.09 Inline With $2.09B Estimate

Deep-pocketed investors have adopted a bearish approach towards Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ICLR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Icon. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 20% leaning bullish and 80% bearish. Among these notable options, 5 are puts, totaling $226,355, and 5 are calls, amounting to $143,362.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $280.0 to $310.0 for Icon during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Icon stands at 1.0, with a total volume reaching 1,030.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Icon, situated within the strike price corridor from $280.0 to $310.0, throughout the last 30 days.
<h3>Icon 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713296776_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$5.6</td>
<td>$5.1</td>
<td>$5.6</td>
<td>$280.00</td>
<td>$70.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.3</td>
<td>$280.00</td>
<td>$44.1K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$6.5</td>
<td>$6.1</td>
<td>$6.5</td>
<td>$280.00</td>
<td>$39.6K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">311</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$6.9</td>
<td>$6.9</td>
<td>$6.9</td>
<td>$280.00</td>
<td>$37.9K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">317</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$6.6</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$280.00</td>
<td>$34.6K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">250</td>
</tr>
</tbody>
</table>

<h3>About Icon</h3>
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Having examined the options trading patterns of Icon, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Icon</h3>
<ul>
<li>With a volume of 439,648, the price of ICLR is down 0.0% at $299.12. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Icon</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $354.0.
<ul>
<li>In a cautious move, an analyst from Mizuho downgraded its rating to Buy, setting a price target of $346. </li>
<li>An analyst from Baird persists with their Outperform rating on Icon, maintaining a target price of $362. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Icon, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At Icon's Recent Unusual Options Activity

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 20 years by 10.4% on an annualized basis producing an average annual return of 18.29%. Currently, Icon has a market capitalization of $25.24 billion. 
Buying $1000 In ICLR: If an investor had bought $1000 of ICLR stock 20 years ago, it would be worth $28,551.43 today based on a price of $306.00 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712957435_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Icon Stock In The Last 20 Years

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and raises the price target from $345 to $362.

Baird Maintains Outperform on Icon, Raises Price Target to $362

Mizuho analyst Ann Hynes reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and maintains $346 price target.

Reiteration

Mizuho Reiterates Buy on Icon, Maintains $346 Price Target

Management

ICON Announces CFO Transition, Brendan Brennan, Will Leave His Role At Icon In Q4 This Year; Co Reaffirmed Its Previously Announced Full Year 2024 Guidance; Commenced A Search To Identify Next CFO

ICON CFO Brendan Brennan To Leave Role In Q4

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 15 years by 8.95% on an annualized basis producing an average annual return of 22.3%. Currently, Icon has a market capitalization of $27.39 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $2,070.48 today based on a price of $332.00 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711377013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Icon Stock In The Last 15 Years

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 20 years by 11.84% on an annualized basis producing an average annual return of 19.81%. Currently, Icon has a market capitalization of $28.05 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 20 years ago, it would be worth $3,859.89 today based on a price of $340.00 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709911823_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Icon 20 Years Ago Would Be Worth Today

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 5 years by 4.31% on an annualized basis producing an average annual return of 17.03%. Currently, Icon has a market capitalization of $25.85 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 5 years ago, it would be worth $213.15 today based on a price of $313.37 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708711217_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.
Shares of NICE Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nice#NASDAQ">NICE</a>) rose sharply during Thursday&rsquo;s session after the company reported better-than-expected fourth-quarter financial results and <a href="https://www.benzinga.com/news/earnings/24/02/37264405/nices-q4-results-surpasses-expectations-cloud-revenue-soars-sets-bold-2024-targets">issued FY24 guidance above estimates</a>.
NICE reported fourth-quarter fiscal 2023 revenue growth of 9.6% year-over-year to $623.19 million, beating the consensus of $618.51 million. Adjusted EPS improved to $2.36 compared to $2.04 in the prior year, beating the consensus of $2.28.
NICE shares jumped 10.4% to $249.39 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) shares shares rose 40.8% to $12.21 after posting better-than-expected fourth-quarter results.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) gained 34.7% to $5.36. Novavax has reached a settlement related to the 2021 advance purchase agreement for Novavax&#39;s prototype Covid-19 vaccine (NVX-COV2373).</li>
<li>Mativ Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/matv#NYSE">MATV</a>) climbed 27.6% to $15.00 following upbeat earnings.</li>
<li>Outset Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/om#NASDAQ">OM</a>) rose 26% to $4.0680 following upbeat results.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) climbed 22.2% to $9.19 after announcing a $325.0 million private placement.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) shares gained 19.5% to $21.13 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) climbed 19.3% to $18.13. B. Riley&rsquo;s board issued a statement regarding internal review.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) gained 19.2% to $875.07. Supermicro announced a proposed offering of $1.5 billion of convertible senior notes due 2029.</li>
<li>AlTi Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alti#NASDAQ">ALTI</a>) jumped 18.6% to $6.90. AlTi Global announced a strategic investment of up to $450 million by Allianz X and Constellation Wealth Capital.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) gained 17.5% to $18.00 following strong sales results.</li>
<li>ACV Auctions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acva#NASDAQ">ACVA</a>) rose 16.9% to $16.37 after the company reported better-than-expected fourth-quarter financial results and announced the settlement of its antitrust litigation related to the AutoIMS technology platform.</li>
<li>FTI Consulting, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fcn#NYSE">FCN</a>) climbed 15.5% to $219.72 following upbeat results.</li>
<li>NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) gained 15.4% to $778.61 after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.</li>
<li>OUTFRONT Media Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/out#NYSE">OUT</a>) climbed 15.4% to $14.35 following upbeat results.</li>
<li>Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>) gained 14.4% to $64.90 following strong results.</li>
<li>Indivior PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indv#NASDAQ">INDV</a>) rose 13.3% to $19.83 following fourth-quarter results.</li>
<li>Installed Building Products, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibp#NYSE">IBP</a>) gained 12.8% to $228.59 after the company reported better-than-expected fourth-quarter financial results and authorized a $300 million stock repurchase program.</li>
<li>ICON Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclr#NASDAQ">ICLR</a>) rose 12.1% to $319.05 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 guidance.</li>
<li>Celestica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cls#NYSE">CLS</a>) climbed 11.6% to $41.51.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amd#NASDAQ">AMD</a>) rose 11.6% to $183.27 in sympathy with NVIDIA, which reported better-than-expected quarterly financial results and issued revenue guidance above estimates.</li>
<li>Quanta Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pwr#NYSE">PWR</a>) gained 11% to $234.42 after the company reported better-than-expected quarterly financial results and issued guidance.</li>
<li>Synopsys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>) climbed 10.7% to $601.93 after the company reported better-than-expected first-quarter adjusted EPS results and issued strong guidance.</li>
<li>Q2 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtwo#NASDAQ">QTWO</a>) gained 9.5% to $45.82 following strong results.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) gained 9.5% to $95.93 after the company reported fourth-quarter financial results.</li>
<li>Dell Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) rose 8.7% to $88.46.</li>
<li>Wingstop Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wing#NASDAQ">WING</a>) gained 8.4% to $336.34. Wingstop reported better-than-expected results for its fourth quarter on Wednesday.</li>
<li>Royal Caribbean Cruises Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcl#NYSE">RCL</a>) surged 7.9% to $124.00 after the company raised its FY24 adjusted EPS guidance. Also, the company said demand and bookings has exceeded expectations.</li>
<li>DigitalOcean Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docn#NYSE">DOCN</a>) rose 6.8% to $38.29 following upbeat results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37254407/jim-cramer-unity-software-had-problems-but-zscaler-is-a-good-one-to-buy"> Jim Cramer: Unity Software &#39;Had Problems,&#39; But Zscaler Is A &#39;Good One&#39; To Buy </a>

WIIM

ICON shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 guidance.

<ul>
<li>Re-affirming full-year 2024 financial guidance of revenue of $8,400 - $8,800 million, representing a year over year increase of 3.4% to 8.4%, and adjusted earnings per share&#x2A; in the range of $14.50 - $15.30, representing a year over year increase of 13.4% to 19.6%. Adjusted earnings per share to exclude amortization, stock compensation, restructuring, foreign exchange and transaction-related / integrated-related adjustments.</li>
</ul>
We remain encouraged by the positive demand environment as we enter this year, and as such, reaffirm our previously issued financial guidance for the full year 2024, with revenue in the range of $8,400 - $8,800 million, and adjusted earnings per share in the range of $14.50 - $15.30."

Guidance

ICON Reaffirms FY24 EPS $14.50-$15.30 Vs $14.91 Est.; Revenue $8.4B-$8.8B Vs $8.66B Est.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) reported quarterly earnings of $3.46 per share which beat the analyst consensus estimate of $3.45 by 0.29 percent. This is a 10.54 percent increase over earnings of $3.13 per share from the same period last year. The company reported quarterly sales of $2.07 billion which missed the analyst consensus estimate of $2.09 billion by 1.19 percent. This is a 5.31 percent increase over sales of $1.96 billion the same period last year.

Icon Q4 Adj. EPS $3.46 Beats $3.45 Estimate, Sales $2.07B Miss $2.09B Estimate

ALIT

AMSF

ANSS

ATNI

BALY

BELFA

BELFB

BLCO

BRDG

BROS

BRSP

CAKE

CCAP

CCRN

CCSI

CENX

CHDN

CHRD

CNNE

COKE

CSTE

CSTM

DINO

ECPG

ERII

ESEA

ETSY

EXAS

FIVN

GATO

GKOS

GLBE

GOOD

GRMN

GSHD

INSG

IONS

JACK

JOBY

KALU

LANV

LCID

LIVN

LUNG

MGRC

MTLS

NDSN

NEXA

NGVT

NOVA

NVRO

NYMT

OBDC

Earnings Scheduled For February 21, 2024

Icon Q1 2024 Earnings Preview

Icon Non-GAAP EPS of $2.90 misses by $0.51, revenue of $2.09B in-line

ICON adjusts 2024 revenue, EPS guidance ranges

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Icon (NASDAQ:<a href="https://investorplace.com/stock-quotes/iclr-stock-quote/">ICLR</a>) just reported results for the first quarter of 2024.<ul><li>Icon reported earnings per share of $3.47. This was above the analyst estimate for EPS of $3.41.</li><li>The company reported revenue of $2.09 billion.</li><li>This was same as the analyst estimate for revenue of $2.09 billion.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/iclr-stock-earnings-icon-for-q1-of-2024/">ICLR Stock Earnings: Icon Beats EPS, Meets Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICLR Stock Earnings: Icon Beats EPS, Meets Revenue for Q1 2024

ICON Public Limited Company 2024 Q1 - Results - Earnings Call Presentation

ICON Public Limited Company (ICLR) Q1 2024 Earnings Call Transcript

Icon (ICLR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 24. Analyst Ann Hynes from Mizuho Sec...

Buy Rating Affirmed for Icon Based on Strong Financials and Growth Potential

Barclays analyst Luke Sergott maintained a Buy rating on Icon (ICLR – Research Report) today and set a price target of $355.00. The company's share...

Barclays Remains a Buy on Icon (ICLR)

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Icon (ICLR – Research Report). The company's shares cl...

Icon (ICLR) Receives a Buy from Truist Financial

ICON announces pricing of $2B notes

Press Releases

Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON

ICON Issues Financial Guidance for Full Year 2024

New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment